Retatrutide Hair Loss: Does It Cause Shedding, and Will It Grow Back?

Probably, for some people, but none of the six retatrutide Phase 3 trials that have reported gives a hair loss rate, as of October 2026. The case for expecting retatrutide hair loss comes from its closest relatives: the FDA labels for tirzepatide (Zepbound) and semaglutide (Wegovy) list hair loss in 3% to 6% of people, mostly women, and both labels link it to weight reduction. In the one head-to-head trial so far, retatrutide 12 mg took off more than twice the weight that Ozempic 2 mg did. Hair lost after fast weight loss usually grows back.

Retatrutide's own trial reports can't settle this yet, so most numbers below come from the tirzepatide and semaglutide labels, marked as class evidence, and from NIH and NHS guidance on shedding. Everything here was checked on October 31, 2026.

Retatrutide hair loss in the trials so far

Six Phase 3 trials have reported positive results: TRIUMPH-4, TRANSCEND-T2D-1, TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 and, on October 28, 2026, TRANSCEND-T2D-2. None of Lilly's releases gives a hair loss rate. They list the common effects, led by nausea, diarrhea, constipation and vomiting, plus a skin-sensation effect called dysesthesia (the full rundown is on our side effects page). A press release only carries the effects Lilly picks, so people in those trials may still have lost hair.

Three of the six now have journal papers: TRANSCEND-T2D-1 and TRIUMPH-2 in The Lancet, and TRIUMPH-1 in the New England Journal of Medicine. None of the three abstracts mentions hair. On safety, TRIUMPH-1's says: "The most common adverse events were gastrointestinal." The full safety tables are paywalled and we couldn't check them, so a figure may already be in print. TRIUMPH-3, TRIUMPH-4 and TRANSCEND-T2D-2 have no paper yet.

The chart below shows how much weight people lost on 12 mg in each of those six trials, all of them still without a published hair loss rate.

The Phase 2 trials give a firmer clue. ClinicalTrials.gov lists every side effect reported by 5% or more of any group in the 48-week obesity trial (338 adults) and the 36-week diabetes trial (281 adults). Hair loss and alopecia appear in neither table. So in every dose group, fewer than 5% of people reported hair loss.

In head counts, the obesity trial's 12 mg group had 62 people, who lost 24.2% of their body weight on average by week 48 in the NEJM paper. A 5% ceiling caps hair loss in that group at 3 people, since 3 of 62 is 4.8% and 4 would be 6.5%. In the two 33-person 4 mg groups, the cap is 1 person each.

That ceiling is about the size of tirzepatide's label rate, so groups this small can't show that retatrutide is gentler on hair. What they do show is that no Phase 2 dose group reached 1 in 20 people with hair loss. The obesity trial was also 51.8% men, and on the approved drugs men rarely report hair loss at all. People on r/Retatrutide have started threads titled "Hair fall" and "Hair Loss on Retatrutide?", but forum posts can't tell you how common it is or what caused it. Our retatrutide Reddit roundup checks other forum claims against the trials.

How often tirzepatide and semaglutide cause hair loss

Tirzepatide and semaglutide share retatrutide's GLP-1 action, and tirzepatide shares its GIP action too. Until a retatrutide figure is published, their FDA labels are the best stand-in. That's class evidence, not retatrutide data.

The Wegovy and Zepbound rates come from each label's pooled trials. For retatrutide, "under 5%" is the Phase 2 reporting ceiling worked out above, not a measured rate.

Sex makes the biggest difference. On Zepbound, 7.1% of women reported hair loss against 0.5% of men, roughly 1 in 14 women and 1 in 200 men. On Wegovy the split was 4% of women and 0.9% of men on 2.4 mg, widening to 8.4% and 0.2% on 7.2 mg. No one on Zepbound stopped treatment because of hair loss in its trials.

Dose tells a mixed story. Wegovy's rate nearly doubled from 2.4 mg to 7.2 mg, 3.3% to 5.8%. Zepbound's stayed between 4% and 5% at every dose from 5 mg to 15 mg.

What the head-to-head trials add

TRANSCEND-T2D-2 put retatrutide against Ozempic 2 mg (semaglutide) for 80 weeks in 1,298 adults with type 2 diabetes. On Lilly's efficacy estimand, people on 12 mg lost 20.9% of their body weight against 9.4% on Ozempic. The release compares the two groups on seven side effects, including diarrhea, nausea and dysesthesia, and hair isn't one of them. The trial was also open label, so people knew which drug they were on, which can sway how symptoms get reported.

TRIUMPH-5, retatrutide against tirzepatide in adults with obesity, has an estimated primary completion of November 2026 on ClinicalTrials.gov, and our retatrutide vs tirzepatide page will cover any hair loss figures it brings.

Our read: retatrutide took off more than twice Ozempic's weight loss in the same trial, so we'd expect its hair loss rate to land inside or near the labels' 3% to 6% band once it's published, with women reporting most of it. The flat Zepbound numbers and the Phase 2 ceiling of 5% per group are reasons not to assume it will climb far past that.

Why weight loss makes hair shed

Each scalp hair grows for 2 to 6 years, rests for several months, then falls out and is replaced, according to MedlinePlus Genetics. The NHS puts ordinary shedding at 50 to 100 hairs a day, often without you noticing.

After a physical or emotional shock, far more hairs than usual can stop growing and then fall out together, weeks to months later. This is telogen effluvium (resting-phase shedding), and MedlinePlus lists crash diets, especially ones without enough protein, among its triggers, alongside high fever, major surgery, childbirth and severe stress. Hair tends to come out in handfuls in the shower or on the brush. If you've had a baby in the past few months, that alone can explain it; our pregnancy and fertility page covers retatrutide around pregnancy.

Retatrutide cuts appetite hard. In TRIUMPH-4, 19.0% of people on 9 mg and 18.2% on 12 mg reported decreased appetite as a side effect, against 9.4% on placebo, and those groups lost 26.4% and 28.7% of their weight on average over 68 weeks (Lilly's efficacy estimand). Eating far less, fast, looks a lot like the crash-diet trigger MedlinePlus describes. Protein matters twice over here, because the same shortfall also costs muscle, which our muscle loss page covers.

When shedding starts, and how long it lasts

In the Phase 3 trials, everyone started at 2 mg and stepped up every 4 weeks. People aiming for 12 mg went through 4, 6 and 9 mg and reached 12 mg at week 17.

Weight comes off fastest early. In the Phase 2 obesity trial, the 12 mg group had lost 17.5% by week 24 and 24.2% by week 48, so about 72% of the 48-week weight loss happened in the first 24 weeks. That's our arithmetic from the NEJM figures, and our weight loss timeline shows the pace week by week.

MedlinePlus says you may not notice telogen shedding for weeks to months after the trigger, and that it eases over 6 to 8 months. Line the two timelines up and the likeliest window for extra hair on the brush opens a few months after the first dose, during or just after the steepest weight loss.

Our read: shedding that starts a few months into treatment and fades over the following 6 to 8 months fits the weight-loss pattern above. Shedding in the first week or two, or hair loss that is still getting worse after a year, doesn't fit it, and that's worth a doctor's look.

Does retatrutide damage hair follicles?

Nobody has tested that in people taking retatrutide. We found no published retatrutide study that examined scalps or measured hair density. The tirzepatide and semaglutide labels word their finding the same way: hair loss was "associated with weight reduction". That fits telogen effluvium, where follicles pause and then restart, rather than damage that stops them working.

Pattern hair loss is a separate condition. It usually runs in families, according to the NHS, and it's permanent. In men it starts above the temples, and in women the part widens on top, as MedlinePlus Genetics describes it. If your thinning follows one of those shapes, bring that up with your doctor, because it won't reverse on its own.

A sore, burning or tingly scalp without much shedding sounds more like a different side effect. Retatrutide causes a skin-sensation problem called dysesthesia, reported by 12.5% of people on 12 mg in TRIUMPH-1 against 0.9% on placebo, and by 6.5% on 12 mg against 2.7% on Ozempic in TRANSCEND-T2D-2.

If your retatrutide didn't come from a trial, there's another suspect. Anyone weighing retatrutide for sale online should know that Australia's TGA tested one vial sold as retatrutide (alert dated September 14, 2026) and found no retatrutide at all, only undeclared semaglutide at about 8 times the level in approved products. No approved version exists yet, and Lilly's October 2026 FAQ warns that illicit products can hold the wrong ingredient, too much or too little of it, or contaminants. Hair loss on an unverified vial can't be pinned on retatrutide, or on anything else.

What helps while your hair is shedding

Most hair loss needs no treatment, according to the NHS, because it's either temporary or part of getting older. These steps come from general hair loss guidance, not from retatrutide studies:

• Check whether it's more than normal. Losing 50 to 100 hairs a day is ordinary (NHS), and MedlinePlus gives a normal range of 50 to 200. Handfuls in the shower or a wider part are what telogen shedding looks like.
• Keep protein up even when you aren't hungry. MedlinePlus names low-protein crash diets as a trigger. Ask your doctor or a dietitian for a daily target that fits your weight and kidneys.
• Ask whether blood tests make sense if shedding is heavy or won't ease. The NHS lists iron deficiency as a cause of temporary hair loss, and MedlinePlus lists thyroid disease and anemia.
• Be gentle with it. MedlinePlus lists heavy shampooing and blow-drying and tight hairstyles as causes of hair loss in their own right.
• Know what minoxidil is for. The NHS lists it as a main treatment for pattern hair loss, and it only works for as long as you use it.
• Be careful with add-on peptides sold for hair. Some people add GHK-Cu, but nobody has tested whether it changes shedding after weight loss, as our page on retatrutide and GHK-Cu explains.
• Leave dose changes to your prescriber or trial team. Shedding is a fair thing to raise at a dose review, even though no one has shown that a lower dose shortens it.

When hair loss needs a doctor

None of those fit plain weight-loss shedding. A doctor can often tell the cause by examining your hair and scalp, and blood tests are rarely needed, according to MedlinePlus. For how long other retatrutide side effects tend to hang around, see how long side effects last.

If you're in a retatrutide trial, report any shedding to the study team, even if it seems minor. Those reports feed the side effect tables that will finally put a real number on retatrutide hair loss.